Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping MutationsPaul K. Paik, Xiuning Le, Julien Mazières et al.|New England Journal of Medicine|2020Cited by 879
Abstract 3385: Liquid biopsy to detect <i>MET</i> exon 14 skipping (<i>MET</i>ex14) and <i>MET</i> amplification in patients with advanced NSCLC: Biomarker analysis from VISION studyXiuning Le, Paul K. Paik, Dariusz M. Kowalski et al.|Cancer Research|2020Cited by 9
Primary efficacy and biomarker analyses from the VISION study of tepotinib in patients (pts) with non-small cell lung cancer (NSCLC) with <i>MET</i>ex14 skipping.Xiuning Le, Paul K. Paik, Enriqueta Felip et al.|Journal of Clinical Oncology|2020Cited by 4